Bionex Acquires 10.5 Billion KRW Stake in Japanese Cancer Treatment Developer, Holding 5.8% Share
[Asia Economy Reporter Yoo Byung-don] Binex announced on the 12th that it will additionally acquire 256,871 shares of the Japanese cancer treatment developer Noile-Immune Biotech for approximately 10.5 billion KRW.
After acquiring the shares, the stake will be 5.8%. The scheduled date for the share acquisition is the day of the announcement.
Hot Picks Today
As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- Man in His 30s Dies After Assaulting Father and Falling from Yongin Apartment
- Samsung Union Member Sparks Controversy With Telegram Post: "Let's Push KOSPI Down to 5,000"
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
Binex stated that the purpose of this share acquisition is a "strategic entry into the next-generation solid tumor CAR-T treatment market."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
